Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) received a third consecutive purchase order from Pharmalink for 60,000 units of Sky Premium Life in the UAE, taking cumulative orders to 270,000 units since June 2024.
The order follows prior purchases of 130,000 and 80,000 units and advances Cosmos toward a 3 million‑unit five‑year partnership goal with Pharmalink.
Cosmos Health (NASDAQ:COSM) reported no material operational impact from the Iran and Middle East conflict and said record revenue momentum continues. Q3 2025 revenue reached $17.1M (+38% YoY); gross profit $2.6M (+116%) with a 15.21% margin; cash rose to $4.63M from $0.66M.
The company said U.S. rollout of NOOR collagen is on track, produced in GMP/FDA-registered facilities, and projected to exceed $12M revenue within 12 months with ~75% gross margins.
Cosmos Health (NASDAQ:COSM) will launch Liv18™ in the U.S. in Q2 2026, a 600 mg/day liver health supplement powered by patented BergacynFF®, supported by two randomized, double‑blind, placebo‑controlled trials showing 9–15% liver fat reduction versus placebo.
Products are manufactured in GMP, FDA‑registered U.S. facilities and target the $4.6B U.S. liver supplements market.
Cosmos Health (NASDAQ:COSM) announced that C-Scrub Wash 4%, made by subsidiary Cana Laboratories, successfully completed testing under EN 12791:2016+A1:2017, the European surgical hand disinfection standard. The independent QACS study confirmed effective antimicrobial activity for surgical hand antisepsis.
The company says this supports expansion into hospital, surgical, and institutional healthcare channels, strengthens the C-Scrub brand, and complements growing commercial availability in the United Kingdom.
Cosmos Health (NASDAQ:COSM) reports record revenue, improving operating metrics, and significant U.S. expansion with locally manufactured Sky Premium Life products. Management projects ~75% gross margins for U.S. operations and expects NOOR Collagen to generate >$12M annualized revenue.
The company entered an LOI to buy an $11.5M pharmacy distribution network, holds >$18M in non-core assets, and will issue updated guidance after FY2025 results.
Cosmos Health (NASDAQ:COSM) announced on March 11, 2026 the purchase of $600,000 of Bitcoin, raising its total digital asset holdings to $3.1 million across Bitcoin and Ethereum. The company described the buys as part of a disciplined treasury strategy to diversify the balance sheet and maintain financial flexibility.
Management said these digital assets may be monetized if needed to address a discount to book value and to support shareholder-value initiatives.
Cosmos Health (NASDAQ:COSM) entered a 90-day LOI dated March 6, 2026 to acquire a pharmacy distribution network that currently generates approximately €10 million (≈$11.5 million) in annual gross revenue. The network serves broad pharmacy customers in Greece and would integrate with CosmoFarm’s automated logistics to drive efficiencies. The acquisition remains subject to a definitive agreement and customary closing conditions and is presented as part of Cosmos Health’s strategy to help achieve its 2027 revenue guidance of $155.8 million through organic growth and disciplined acquisitions.
Cosmos Health (NASDAQ:COSM) appointed Dr. Dimitrios Iliopoulos to its Advisory Board on February 24, 2026 to support AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos brings academic, biotech leadership, and AI platform experience, including a Phase 2 AI-derived small molecule program.
Cosmos Health (NASDAQ:COSM) highlighted an estimated $15 million fair market value for its wholly owned real estate portfolio in Athens, exceeding its $13.5 million market capitalization as of Feb 17, 2026. Management is evaluating monetization options — sale, JV, or sale-leaseback — to unlock shareholder value.
The two properties are unencumbered, located in Neo Iraklio and Peristeri, and exclude machinery and equipment from the valuation.
Cosmos Health (NASDAQ:COSM) announced that its antimicrobial cleanser C-Scrub Wash Chlorhexidine 4% is now available through Superdrug in the UK as of Feb 18, 2026. Superdrug operates more than 830 stores and a strong online platform, including over 200 in-store pharmacies.
This listing expands C-Scrub’s retail and pharmacy reach in the UK and Ireland, increasing brand exposure across broad-based and health-focused consumer channels and supporting regional product development plans.